image
Figure 4: iASPP-SV was up-regulated in primary breast cancers, and suppression of iASPP-SV enhanced the sensitivity of MCF-7 to Adriamycin. A. Relative expression levels of iASPP-SV and iASPP (828) in primary breast cancers with p53 wild-type and mutated-type (left figure), and the relation between iASPP-SV and iASPP (828) expression (right figure). B. Knock-down of iASPP-SV enhanced Adriamycin -sensitivity of MCF-7. C. The changes of P53, P21, Bax and Bcl-2 expression in MCF-7 and MDA-MB-231 treated with different dose of Adriamycin for 24 hours, and protein changes in left figure and mRNA changes in right figure D. The changes of p21and Bax expression in MCF-7 and MDA-MB-231 treated with 0.3 μM Adriamycin or not after knock-down of iASPP-SV and iASPP (828), and protein changes in left figure and mRNA changes in right figure. E. MCF-7 cells were treated with 0.3 μM Adriamycin or not after knock-down of iASPP-SV and iASPP (828), and apoptosis levels were assessed by FACS. For relative level of mRNA, the expression level of untreated cell was arbitrary set as 1.
Goto home»